BerandaALNY • NASDAQ
add
Alnylam Pharmaceuticals, Inc.
$258,35
Setelah Jam Perdagangan Normal:(0,00%)0,00
$258,35
Tutup: 8 Mei, 16.00.02 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$276,55
Rentang hari
$245,96 - $270,00
Rentang tahun
$144,80 - $304,39
Kapitalisasi pasar
33,71Â M USD
Volume Rata-Rata
1,07Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 594,19Â jt | 20,20% |
Biaya operasional | 505,07Â jt | 7,05% |
Laba bersih | -57,48Â jt | 12,82% |
Margin laba bersih | -9,67 | 27,51% |
Penghasilan per saham | -0,01 | 93,75% |
EBITDA | 32,48Â jt | 208,57% |
Tarif pajak efektif | -38,18% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,63Â M | 11,00% |
Total aset | 4,21Â M | 10,18% |
Total liabilitas | 4,10Â M | 1,35% |
Total ekuitas | 115,44 jt | — |
Saham yang beredar | 130,39 jt | — |
Harga terhadap nilai buku | 310,73 | — |
Tingkat pengembalian aset | 1,07% | — |
Tingkat pengembalian modal | 1,60% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -57,48Â jt | 12,82% |
Kas dari operasi | -118,31Â jt | -45,14% |
Kas dari investasi | 113,77Â jt | 268,25% |
Kas dari pembiayaan | 44,08Â jt | 52,48% |
Perubahan kas bersih | 53,60Â jt | 141,18% |
Arus kas bebas | -69,51Â jt | 26,61% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.230
